There is no single best medication for rheumatoid arthritis pain because the right choice depends on how severe your disease is, how long you’ve had it, and how your body responds to treatment. But the medical consensus is clear: disease-modifying drugs that slow joint damage are the foundation of RA pain management, not just painkillers. Methotrexate, taken once a week, is the first drug most rheumatologists reach for. If it doesn’t bring enough relief, biologics or newer oral options can be added or substituted.
Why Pain Relief Starts With Slowing the Disease
RA pain comes from your immune system attacking the lining of your joints, causing inflammation, swelling, and eventually joint damage. Painkillers like ibuprofen can take the edge off, but they don’t stop the underlying process. Disease-modifying antirheumatic drugs (DMARDs) do. By dialing down the immune attack, they reduce pain at its source and protect your joints from permanent erosion. Starting a DMARD early, ideally within months of diagnosis, gives you the best chance of keeping pain and joint damage under control long-term.
Methotrexate: The Standard First Choice
Methotrexate is the most widely prescribed DMARD for RA and the treatment most guidelines recommend trying first. It’s taken once a week, typically starting at 10 to 15 mg, either as a pill or injection. It works by broadly suppressing the overactive immune response driving joint inflammation.
The trade-off is patience. Methotrexate doesn’t work overnight. Most people need several weeks to notice improvement, and it can take three months or longer to feel the full effect. During that ramp-up period, your doctor may use other medications to bridge the gap and keep pain manageable. Side effects like nausea and fatigue are common but often improve with dose adjustments or by switching from pills to injections. You’ll also need regular blood tests to monitor your liver and blood cell counts.
NSAIDs and Steroids for Flare-Ups
While you’re waiting for a DMARD to kick in, or when a flare hits despite ongoing treatment, faster-acting medications play an important role. Anti-inflammatory painkillers like ibuprofen and naproxen can reduce swelling and ease pain within hours. For RA, higher doses than you’d use for a headache are often needed to meaningfully cut inflammation. If one NSAID doesn’t help after about four weeks, switching to a different one is reasonable since people respond differently to each formulation.
Corticosteroids (typically prednisone at 5 to 10 mg daily) are more powerful at tamping down inflammation and can provide rapid relief during a bad flare. When the flare is limited to one or two joints, a steroid injection directly into the affected joint can calm things down without changing your overall medication plan. The goal with steroids is always short-term use. Starting doses of 15 to 20 mg daily are sometimes necessary, but doctors aim to taper down below 10 mg within a few weeks because prolonged use carries risks including bone thinning, weight gain, and blood sugar problems.
Biologics: When Methotrexate Isn’t Enough
If methotrexate alone doesn’t control your symptoms adequately, the next step is usually a biologic. These are injectable or infused medications that target specific parts of the immune system rather than suppressing it broadly. The two most common categories block either TNF (a protein that drives inflammation) or IL-6 (another inflammatory signal).
Clinical trials initially suggested IL-6 blockers might work better than TNF blockers when used alone, but real-world registry data from the CorEvitas RA database shows no significant difference in pain scores, disease activity, or the proportion of patients reaching low disease activity between the two classes. About one-third of patients on either type achieved low disease activity. In practice, the choice often comes down to how each drug is administered, how frequently you need doses, and your insurance coverage.
Biologics generally take a few weeks to start working, with meaningful improvement typically appearing around three to four months. Some people notice small changes after the first or second dose, but six months isn’t unusual for the full benefit to emerge. If the first biologic you try doesn’t work well enough, switching to one with a different mechanism often helps.
Biosimilars Can Lower the Cost
Biosimilars are near-identical copies of original biologic drugs, approved through rigorous testing to confirm they work the same way. For adalimumab (the original brand being Humira, one of the most commonly prescribed TNF blockers), biosimilars offer the same therapeutic benefit at a lower price. In one study comparing a biosimilar to Humira in 106 patients, safety outcomes were nearly identical, retention rates were actually higher in the biosimilar group at one year (63% vs. 44%), and median annual treatment costs were roughly $440 lower. If your doctor recommends a biologic, asking about biosimilar options is a practical way to reduce out-of-pocket costs without compromising effectiveness.
JAK Inhibitors: A Pill-Based Alternative
JAK inhibitors are a newer class of oral medications that work differently from both traditional DMARDs and biologics. Instead of targeting a single protein outside the cell, they block signaling pathways inside immune cells that drive inflammation. Two of the most commonly used are tofacitinib and upadacitinib, both taken as daily pills rather than injections.
Efficacy is competitive with biologics. In head-to-head trials, tofacitinib combined with methotrexate performed comparably to adalimumab (a TNF blocker) combined with methotrexate. Upadacitinib at its standard dose matched adalimumab in psoriatic arthritis patients, and higher doses were statistically superior.
Safety is where things get more complicated. A large safety trial of tofacitinib in patients over 50 with cardiovascular risk factors found higher rates of heart-related events, certain cancers, and blood clots compared to TNF blockers. The FDA now recommends tofacitinib only after a TNF blocker has been tried or can’t be used. Upadacitinib’s safety profile has looked more favorable in integrated analyses, with rates of cardiovascular events and cancers similar to adalimumab and methotrexate. However, higher rates of shingles have been observed with upadacitinib. For many people, JAK inhibitors are an effective option, but they’re typically reserved for cases where other treatments haven’t worked well enough.
How Treatment Typically Progresses
RA treatment follows a step-up approach. You start with methotrexate (sometimes combined with short-term steroids for quick relief), give it a few months to work, and escalate if needed. The next step is usually adding or switching to a biologic, often a TNF blocker. If that doesn’t provide enough relief, your rheumatologist may try a different biologic class or a JAK inhibitor. At each stage, NSAIDs can be used alongside your main treatment to manage day-to-day pain.
The goal isn’t just less pain. It’s remission or low disease activity, meaning minimal swelling, stiffness, and joint damage over time. Achieving this usually requires finding the right combination of medications through a process that can take months of adjustment. Regular follow-up visits, typically every three to six months once your treatment stabilizes, help your rheumatologist track whether your current regimen is doing enough or needs to change.
What Affects Which Medication Works Best for You
Several factors shape which medication is most likely to help. How many joints are involved matters: widespread disease with many swollen joints often warrants more aggressive treatment earlier. Blood test results showing high levels of inflammation markers or the presence of specific antibodies (RF and ACPA) can indicate a more aggressive disease course that benefits from earlier use of biologics. Your age, other health conditions, and tolerance for side effects also play a role. Someone with heart disease risk factors, for example, might avoid certain JAK inhibitors in favor of a biologic.
Practical considerations matter too. If the idea of self-injecting a biologic every two weeks feels like a dealbreaker, a daily pill like a JAK inhibitor might improve your adherence. If cost is a barrier, biosimilars or patient assistance programs can make biologics more accessible. The “best” medication is ultimately the one that controls your disease effectively, fits your life, and causes side effects you can live with.